Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Share-based compensation | 74.5 | 67.7 |
| Acquisition accounting inventory fair value step-up adjustment | 37.5 | 29.9 |
| Provision for losses on accounts receivable and inventory | 14.2 | 5.3 |
| Depreciation | 9.1 | 10.4 |
| Non-cash interest expense | 4.7 | 17.1 |
| Deferred tax benefit | (66.2) | (43.8) |
| Gain on sale of priority review voucher | (122.8) | — |
| Other non-cash transactions | 3.9 | (6.5) |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's D&A?
- Jazz Pharmaceuticals (JAZZ) reported D&A of $9.1M in Q1 2026.
- How has Jazz Pharmaceuticals's D&A changed year-over-year?
- Jazz Pharmaceuticals's D&A decreased by 12.5% year-over-year, from $10.4M to $9.1M.
- What is the long-term trend for Jazz Pharmaceuticals's D&A?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's D&A has grown at a 11.7% compound annual growth rate (CAGR), from $26.71M to $41.64M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Jazz Pharmaceuticals's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude